Hepatitis B Reactivation Following COVID-19
We describe the case of a 83-year-old man who received an allogenic stem cell transplant for acute myelogenous leukemia in 2010. He developed mild COVID-19 illness in 2023 and improved without corticosteroids. Elevated serum transaminase levels were noted, with subsequent evaluation showing a hepati...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American College of Physicians
2024-11-01
|
| Series: | Annals of Internal Medicine: Clinical Cases |
| Online Access: | https://www.acpjournals.org/doi/10.7326/aimcc.2024.0253 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | We describe the case of a 83-year-old man who received an allogenic stem cell transplant for acute myelogenous leukemia in 2010. He developed mild COVID-19 illness in 2023 and improved without corticosteroids. Elevated serum transaminase levels were noted, with subsequent evaluation showing a hepatitis B virus (HBV) DNA level measured by polymerase chain reaction of 297 000 000 IU/mL, and positive hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B core antibody (anti-HBc). At baseline, he had a positive anti-HBc and a negative HBsAg. He was treated with entecavir and showed improvement in HBV DNA polymerase chain reaction and serum transaminase levels. Patients with COVID-19 who have persistently elevated serum transaminase levels should be evaluated for HBV reactivation. |
|---|---|
| ISSN: | 2767-7664 |